| 國立臺灣大學 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu, Shang-Ju; Tang, Jih-Luh; Lin, Chien-Ting; Kuo, Yuan-Yeh; Li, Li-Yu; Tseng, Mei-Hsuan; Huang, Chi-Fei; Lai, Yen-Jun; Lee, Fen-Yu; Liu, Ming-Chih; Liu, Chia-Wen; Hou, Hsin-An; Chen, Chien-Yuan; Chou, Wen-Chien; Yao, Ming; Huang, Shang-Yi; Ko, Bor-Sheng; Tsay, Woei; Tien, Hwei-Fang; 蔡偉; 李玢玉; 姚明; 陳建源; 柯博升; 田蕙芬; 劉敏枝; 郭遠燁; 黃聖懿; 吳尚儒; 唐季祿; 周文堅; 侯信安 |
| 臺大學術典藏 |
2021-01-04T12:12:39Z |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu S.-J.; HWEI-FANG TIEN; Tsay W.; Ko B.-S.; Huang S.-Y.; Yao M.; Tang J.-L.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; Chou W.-C. |
| 臺大學術典藏 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
SHANG-JU WU; Chou W.-C.; Chen C.-Y.; Hou H.-A.; Liu C.-W.; Liu M.-C.; Lee F.-Y.; Lai Y.-J.; Huang C.-F.; Tseng M.-H.; Li L.-Y.; Tang J.-L.; Lin C.-T.; Kuo Y.-Y.; Yao M.; Huang S.-Y.; Ko B.-S.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2021-01-06T03:58:35Z |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu S.-J.; JIH-LUH TANG; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Yao M.; Huang S.-Y.; Ko B.-S.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Tang J.-L.; Wu S.-J.; Ko B.-S.; Tsay W.; Tien H.-F.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Yao M.; SHANG-YI HUANG |
| 臺大學術典藏 |
2021-02-05T06:29:35Z |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu S.-J.;Tang J.-L.;Lin C.-T.;Kuo Y.-Y.;Li L.-Y.;Tseng M.-H.;Huang C.-F.;Lai Y.-J.;Lee F.-Y.;Liu M.-C.;Liu C.-W.;Hou H.-A.;Chen C.-Y.;Wen-Chien Chou;Yao M.;Huang S.-Y.;Ko B.-S.;Tsay W.;Tien H.-F.; Wu S.-J.; Tang J.-L.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; WEN-CHIEN CHOU; Yao M.; Huang S.-Y.; Ko B.-S.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:35Z |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu S.-J.; Tang J.-L.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; HSIN-AN HOU; Chen C.-Y.; Chou W.-C.; Yao M.; Huang S.-Y.; Ko B.-S.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2018-09-10T04:06:49Z |
Clinical implications of using racemic drugs
|
Chen, C.-Y.;Shieh, W.-R.;Chen, C.-S.; CHING-YU CHEN |
| 國立臺灣大學 |
1992 |
Clinical Implications of Using Racemic Drugs
|
陳慶餘; 陳慶士; CHEN, CHING-YU; SHIEH, WOAN-RU; CHEN, CHING-SHIH |
| 中國醫藥大學 |
2010-06 |
Clinical Implications, Risk Factors and Mortality Following Community-onset Bacteremia Caused by Extended-spectrum β-lactamase (ESBL) and non-ESBL Producing Escherichia coli.
|
(Chia-Jung Hsieh); (Yea-Huei Shen); 黃高彬(Kao-Pin Hwang)* |
